Repligen Past Earnings Performance
Past criteria checks 0/6
Repligen has been growing earnings at an average annual rate of 15.9%, while the Life Sciences industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 20% per year.
Key information
15.9%
Earnings growth rate
14.4%
EPS growth rate
Life Sciences Industry Growth | 21.5% |
Revenue growth rate | 20.0% |
Return on equity | -0.1% |
Net Margin | -0.3% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Repligen Corporation (NASDAQ:RGEN) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Jul 31We Think Repligen (NASDAQ:RGEN) Can Stay On Top Of Its Debt
Jul 15Repligen: Strong Filtration Growth, Offset By Other Challenges
Jul 13Why We're Not Concerned Yet About Repligen Corporation's (NASDAQ:RGEN) 27% Share Price Plunge
Jun 14Is Now The Time To Look At Buying Repligen Corporation (NASDAQ:RGEN)?
Jun 10Repligen Stock: Still Quite Overvalued
May 30Repligen Corporation Just Missed Earnings - But Analysts Have Updated Their Models
May 03Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)
Apr 30Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet
Apr 15At US$206, Is Repligen Corporation (NASDAQ:RGEN) Worth Looking At Closely?
Feb 13Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)
Jan 08Why We're Not Concerned About Repligen Corporation's (NASDAQ:RGEN) Share Price
Dec 19What Does Repligen Corporation's (NASDAQ:RGEN) Share Price Indicate?
Nov 01Is Repligen (NASDAQ:RGEN) Using Too Much Debt?
Oct 17Is There An Opportunity With Repligen Corporation's (NASDAQ:RGEN) 22% Undervaluation?
Sep 29Things Look Grim For Repligen Corporation (NASDAQ:RGEN) After Today's Downgrade
Aug 09Does Repligen (NASDAQ:RGEN) Have A Healthy Balance Sheet?
Jul 17Is There Now An Opportunity In Repligen Corporation (NASDAQ:RGEN)?
Jul 03With EPS Growth And More, Repligen (NASDAQ:RGEN) Makes An Interesting Case
Jun 19Calculating The Fair Value Of Repligen Corporation (NASDAQ:RGEN)
May 23Repligen (NASDAQ:RGEN) Seems To Use Debt Quite Sensibly
Apr 11Is Now An Opportune Moment To Examine Repligen Corporation (NASDAQ:RGEN)?
Mar 28We Ran A Stock Scan For Earnings Growth And Repligen (NASDAQ:RGEN) Passed With Ease
Mar 08Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)
Feb 20Revenue & Expenses Breakdown
How Repligen makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 602 | -2 | 237 | 42 |
31 Mar 24 | 607 | 15 | 222 | 42 |
31 Dec 23 | 639 | 42 | 216 | 43 |
30 Sep 23 | 670 | 116 | 210 | 44 |
30 Jun 23 | 729 | 138 | 212 | 43 |
31 Mar 23 | 778 | 168 | 218 | 44 |
31 Dec 22 | 802 | 186 | 216 | 44 |
30 Sep 22 | 801 | 166 | 210 | 42 |
30 Jun 22 | 779 | 159 | 204 | 41 |
31 Mar 22 | 734 | 146 | 194 | 39 |
31 Dec 21 | 671 | 128 | 184 | 34 |
30 Sep 21 | 593 | 119 | 164 | 32 |
30 Jun 21 | 509 | 100 | 145 | 27 |
31 Mar 21 | 433 | 80 | 127 | 23 |
31 Dec 20 | 366 | 60 | 116 | 20 |
30 Sep 20 | 327 | 44 | 112 | 19 |
30 Jun 20 | 302 | 31 | 107 | 20 |
31 Mar 20 | 286 | 23 | 100 | 21 |
31 Dec 19 | 270 | 21 | 96 | 19 |
30 Sep 19 | 253 | 23 | 81 | 17 |
30 Jun 19 | 233 | 27 | 72 | 16 |
31 Mar 19 | 210 | 21 | 69 | 16 |
31 Dec 18 | 194 | 17 | 66 | 16 |
30 Sep 18 | 184 | 23 | 64 | 16 |
30 Jun 18 | 171 | 23 | 64 | 14 |
31 Mar 18 | 155 | 29 | 58 | 10 |
31 Dec 17 | 141 | 28 | 52 | 9 |
30 Sep 17 | 125 | 21 | 43 | 8 |
30 Jun 17 | 113 | 18 | 34 | 8 |
31 Mar 17 | 110 | 13 | 31 | 8 |
31 Dec 16 | 105 | 12 | 31 | 7 |
30 Sep 16 | 100 | 7 | 27 | 7 |
30 Jun 16 | 96 | 8 | 28 | 6 |
31 Mar 16 | 88 | 8 | 25 | 6 |
31 Dec 15 | 84 | 9 | 25 | 6 |
30 Sep 15 | 78 | 9 | 23 | 6 |
30 Jun 15 | 74 | 8 | 21 | 6 |
31 Mar 15 | 68 | 7 | 19 | 6 |
31 Dec 14 | 64 | 8 | 16 | 6 |
30 Sep 14 | 63 | 12 | 15 | 6 |
30 Jun 14 | 66 | 16 | 14 | 5 |
31 Mar 14 | 68 | 18 | 13 | 6 |
31 Dec 13 | 68 | 16 | 13 | 7 |
30 Sep 13 | 72 | 22 | 13 | 8 |
Quality Earnings: RGEN is currently unprofitable.
Growing Profit Margin: RGEN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RGEN is unprofitable, but has reduced losses over the past 5 years at a rate of 15.9% per year.
Accelerating Growth: Unable to compare RGEN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RGEN is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-10.8%).
Return on Equity
High ROE: RGEN has a negative Return on Equity (-0.096%), as it is currently unprofitable.